ANCA-Associated Vasculitides: Immunological and Clinical Aspects

Front Matter....Pages i-xix
Friedrich Wegener and the Nature of Fame....Pages 1-4
Front Matter....Pages 5-5
Pathogenic Potential of Anti-Neutrophil Cytoplasmic Autoantibodies....Pages 7-15
Neutrophilic Leukocyte Granules: From Structure to Function....Pages 17-33
Pathogenetic Aspects of Autoantibodies to Endothelial Cells in Systemic Vasculitis....Pages 35-44
Membrane Surface Proteinase 3 Expression and Intracytoplasmic Immunoglobulin on Neutrophils from Patients with ANCA-Associated Vasculitides....Pages 45-50
A New Approach to the Molecular Characterization of the C-ANCA Antigen in Wegener’s Granulomatosis....Pages 51-54
Proteinase 3: Substrate Specificity and Possible Pathogenetic Effect of Wegener’s Granulomatosis Autoantibodies (C-ANCA) by Dysregulation of the Enzyme....Pages 55-60
Inhibition of Proteinase 3 Activity by Peptides Derived from Human Epidermis....Pages 61-64
Implications of c-ANCA Testing for the Classification of Wegener’s Granulomatosis: Performance of Different Detection Systems....Pages 65-70
ANCA and IgG Subclasses....Pages 71-75
Anti-MPO Antibody (Id) and Autoantibody to Purified Anti-MPO F(Ab)2 (Anti-Id)....Pages 77-80
Cross-Reactivity between Antibodies to Thyroid Microsomal Antigens and Myeloperoxidase....Pages 81-85
Antineutrophil Cytoplasmic Autoantibodies (ANCA) Recognizing a Recombinant Myeloperoxidase Subunit....Pages 87-92
Pooled Human IgG (PHIG) Inhibits the Binding of Anti-Myeloperoxidase Antibodies to Myeloperoxidase....Pages 93-96
Studies to Demonstrate Inhibition of Functional Activity of Neutrophil Lysosomal Enzymes with ANCA....Pages 97-100
Lactoferrin Co-Purifies with Myeloperoxidase and is Recognised by Anti-Neutrophil Cytoplasm Antibodies....Pages 101-104
ANCA Specificities for HL-60 and Neutrophil Constituents....Pages 105-108
In Vitro Interactions of C-ANCA (Antibodies to Proteinase 3) with Human Endothelial Cells....Pages 109-113
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Increase Neutrophil Adhesion to Cultured Human Endothelium....Pages 115-119
Myeloperoxidase Binds to Vascular Endothelial Cells, is Recognized by ANCA and can Enhance Complement Dependent Cytotoxicity....Pages 121-123
Front Matter....Pages 5-5
Vascular Permeability Changes Induced by Antibodies to Myeloperoxidase....Pages 125-127
Endothelium, Myeloperoxidase, Anti-Myeloperoxidase Interaction in Vasculitis....Pages 129-132
Further Characterization of an Animal Model of Systemic Vasculitis....Pages 133-137
Induction of an Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase(MPO) in Brown-Norway(BN), Lewis and Wistar Kyoto(WKY) Rat Strains....Pages 139-142
Front Matter....Pages 143-143
Disease Associations with Anti-Neutrophil Cytoplasmic Antibodies....Pages 145-155
Classification of Vasculitis....Pages 157-163
Classification of Systemic Vasculitis — A Pathologist’s View....Pages 165-172
Polyarteritis Nodosa and Churg-Strauss Syndrome an Internist’s View....Pages 173-184
Vasculitis from the Rheumatologist’s Viewpoint....Pages 185-195
A Nephrological View of the Classification of Vasculitis....Pages 197-208
The Nosology of Wegener’s Granulomatosis Utilizing the Elk Format Augmented by C-ANCA....Pages 209-215
Vasculitis — The Neurologist’s View....Pages 217-226
Treatment of Chronic Idiopathic Systemic Vasculitides....Pages 227-234
Monoclonal Antibody Therapy for Vasculitis....Pages 235-238
Heterogeneity of ANCA Sera Showing Atypical, Peripheral and Classical Cytoplasmic Immunofluorescence Patterns....Pages 239-243
ANCA in Systemic Vasculitides, Collagen Vascular Diseases, Rheumatic Disorders and Inflammatory Bowel Diseases....Pages 245-251
Perinuclear Antineutrophil Cytoplasmic Antibodies (P-ANCA): Clinical Significance and Relation to Antibodies Against Myeloid Lysosomal Enzymes....Pages 253-256
Methods of Detection of Anticathepsin G Autoantibodies in Human....Pages 257-261
Anti-Myeloperoxidase Antibodies and Associated Diseases....Pages 263-266
Autoantibodies Directed Against Lysozyme: A New Target Antigen for Anti-Neutrophil Cytoplasmic Antibodies (ANCA)....Pages 267-272
Front Matter....Pages 143-143
Clinical Significance of ANCA in 98 Patients....Pages 273-279
Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA): Antigenic Specificities and Clinical Associations....Pages 281-286
Significance of Autoantibodies to Purified Proteinase 3 in Systemic Vasculitis....Pages 287-289
Characterization of Anti-Myeloperoxidase Antibodies in Vasculitis....Pages 291-294
Low Predictive Value of C-ANCA and Anti-α -Granule Antibody for Vasculitis in Hong Kong....Pages 295-298
Detection and Clinical Associations of Autoantibodies to Myeloid Granular Proteins....Pages 299-302
Relationship Between Disease Activity and ANCA Level by Elisa in the Long-Term Management of Vasculitis....Pages 303-304
ANCA in Ocular Inflammatory Disorders....Pages 305-307
Head and Neck Involvement in Wegener’s Granulomatosis (WG)....Pages 309-313
Orbital Involvement in Wegener’s Granulomatosis....Pages 315-317
MRI of the Head in Wegener’s Granulomatosis....Pages 319-321
The Clinical, Serologic, and Immunopathologic Heterogeneity of Cutaneous Leukocytoclastic Angiitis....Pages 323-326
No ANCA in Thromboangiitis Obliterans (Bürger’s Disease)....Pages 327-330
Alpha-1-Proteinase Inhibitor and Pulmonary Haemorrhage in Systemic Vasculitis....Pages 331-335
Alpha-1-Antitrypsin, CRP and Interleukin-6 in ANCA-positive Vasculitis....Pages 337-340
Pro- and Anti-Inflammatory Cytokines in Primary Systemic Vasculitis....Pages 341-344
Problems of Classification in Necrotizing Vasculitis....Pages 345-348
Anti-Neutrophil Cytoplasm Antibodies in HIV Infection....Pages 349-352
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) and Infection....Pages 353-356
Anti-Lactoferrin Antibodies in Patients with Rheumatoid Arthritis with Vasculitis....Pages 357-362
Front Matter....Pages 143-143
Anti-Neutrophil Cytoplasmic Antibodies in Giant Cell Arteritis and Polymyalgia Rheumatica....Pages 363-366
Antibodies to Neutrophil Cytoplasmic Antigens in Rheumatoid Arthritis....Pages 367-370
Incidence and Specificity of p-ANCA in Rheumatic Diseases....Pages 371-373
Anti-Granulocyte Perinuclear Antibodies but Not Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Rheumatoid Arthritis....Pages 375-380
Anti-Neutrophil Cytoplasmic Antibodies in Patients with Systemic Lupus Erythematosus....Pages 381-384
ANCA with Specificity for Lactoferrin in Systemic Lupus Erythematosus (SLE)....Pages 385-387
Serum Markers of T-Cell Activation in Relapses of Wegener’s Granulomatosis....Pages 389-392
Presence of Anticardiolipin Antibodies Discriminates Between Wegener’s Granulomatosis and Microscopic Polyarteritis....Pages 393-396
Increased Expression of CD 25 and Adhesion Molecules on Peripheral Blood Lymphocytes of Patients with Wegener’s Granulomatosis (WG) and ANCA Positive Vasculitides....Pages 397-404
Wegener’s Granulomatosis with Severe Peripheral and Central Neuropathy — Case Report....Pages 405-409
Limited Prognostic Value of Changes in Antineutrophil Cytoplasmic Antibody Titers in Patients with Wegener’s Granulomatosis....Pages 411-414
Wegener’s Granulomatosis and Henoch-Schönlein Purpura in a Family with Hereditary C4 Deficiency....Pages 415-418
Little Evidence for Anti-Endothelial-Cell Antibodies in Microscopic Polyarteritis and Wegener’s Granulomatosis....Pages 419-422
Prevalence of ANCAs in Patients on Maintenance Haemodialysis....Pages 423-425
Rhabdomyolysis in Vasculitis....Pages 427-430
Rapidly Progressive Glomerulonephritis (RPGN): Is there Still an “Idiopathic” Subgroup?....Pages 431-434
Association between Silica Exposure and Necrotizing Crescentic Glomerulonephritis with p-ANCA and anti-MPO Antibodies: A Hospital-Based Case-Control Study....Pages 435-440
ANCA and Anti-GBM Antibodies in RPGN....Pages 441-444
P-ANCA with Myeloperoxidase Antibodies and C-ANCA with Proteinase 3 Antibodies Define a Different Vasculitis Entity in Patients with Renal Involvement....Pages 445-447
Antineutrophil-Cytoplasmic-Autoantibodies in Poststreptococcal Nephritis....Pages 449-453
Front Matter....Pages 143-143
Indentification of Apparent Dual ANCA Specificities in a Subset of Patients with Systemic Vasculitis and Crescentic Glomerulonephritis....Pages 455-459
C-ANCA and p-ANCA Positive Vasculitis with Crescentic Glomerulonephritis: The Same Clinical Feature but Different Immunological Pathways ?....Pages 461-464
Clinical Manifestations in Patients on Chronic Dialysis with High Titres of ANCA....Pages 465-468
Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitis....Pages 469-472
Cyclosporin a Therapy for Wegener’s Granulomatosis....Pages 473-476
Necrotizing Vasculitis — Relapse Despite Cytotoxic Therapy....Pages 477-481
Effectiveness of Cyclophosphamide Pulse Treatment in Wegener’s Granulomatosis....Pages 483-486
Treatment of Wegener’s Granulomatosis with Intravenous Immunoglobulin....Pages 487-489
Treatment of Wegener’s Granulomatosis....Pages 491-495
Treatment Modalities and ANCA in Takayasu’s Arteritis....Pages 497-501
Late Recurrence of Systemic Vasculitis after Kidney Transplantation Involving the Kidney Allograft....Pages 503-506
P-ANCA of Undefined Specificity in Ulcerative Colitis: Correlation to Disease Activity and Therapy....Pages 507-513
Anti-Neutrophil Cytoplasmic Auto-Antibodies (ANCA) in Patients with Ulcerative Colitis (UC): Influence of Disease Activity and Familial Study....Pages 515-518
Antineutrophil Antibodies in Inlammatory Bowel Disease Recognize Different Antigens....Pages 519-522
Antineutrophil Cytoplasmic Auto-Antibodies in Sera from Patients with Ulcerative Colitis after Proctocolectomy with Ileo-Anal Anastomosis....Pages 523-525
P-ANCA as a Diagnostic Marker in Ulcerative Colitis....Pages 527-531
Lactoferrin, Anti-Lactoferrin Antibodies and Inflammatory Disease....Pages 533-538
Detection of Antineutrophil Cytoplasmatic Antibodies (ANCA) and their Association with other Autoantibodies in Patients with Hepatobiliary Disorders....Pages 539-544
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Autoimmune Liver Disease....Pages 545-549
Back Matter....Pages 551-552